...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!

Fouremm,

As much i hate to say this, I strongly feel that DM is too stubborn to step aside his CEO role for a much much more accomplished experienced biotech executive with BP in their resume. He could easily run the BOD   There may come a point that a BP gets sticky fingers to take a plunge in a buyout of Zenith  but probably not even near the valuation DM is expecting or wanting.  That there  lies the problem,....If Zenith had  a new experience well respected Biotech/BP executive they might get the respect from a biddding BP that DM doesn't get to this point , just food for thought all in my humble opinion,... I hope i am wrong and DM get the proper  Zenith Valuation once a deal is determined ....

Share
New Message
Please login to post a reply